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INTRODUCTION 
 Use of radionuclides to image the skeletal system for early 
detection of focal pathology is referred to as bone scan. Bone scan can 
pick up the asymptomatic alterations in the skeletal system much 
earlier than their appearance on conventional radiographs. Bone scan 
is used in multiple pathologies concerning the skeletal system such as 
in detection of primary bone cancer, cancers spread to bone from 
other primary sites, skip lesions or involvement of multiple bones. 
Bone scans can also be useful in detecting different benign conditions 
of bone likeinflammation or infection causing bone destruction or 
pathological fractures. Bone scan has an advantage over other 
conventional imaging modalities in that it images the entire skeletal 
system and also considers the aspect of remodelling & bone 
mineralization, thus acting as a functional imaging modality rather 
than simply imaging the anatomy. 5-15% change in the turnover of 
bone can be picked up by bone scan, irrespective of the 
pathology.Radiation exposure by a single bone scan is 6.3 mSv.This is 
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far less as compared to a CT scan (3.5-25 mSv) or a PET CT (22-23 
mSv) [1]. 
 Bone scan utility in early breast cancer is a topic for debate. 
Bone scan is a very sensitive imaging modality for detection of 
skeletal metastases, but its specificity is comparatively low. 
 Various series have reported the false positivity around 10-
22%and the false negative rate up to 10%. The false positivity can be 
due to multiple factors such as the type of equipment, technique of 
scanning, expertise of the reporting physician and also on the 
subsequent work up of the areas of abnormal uptake. 
 In a study by Robinson Baker et al[2], radiographs confirmed 
metastases in only 1.5% of the stage I & II breast cancer patients with 
baseline abnormal bone scan. None of the patients with uptake in 
baseline bone scan, but non confirmatory radiographs,progressed over 
the follow up period. Many authors do not recommend baseline bone 
scanning in early breast cancer due to its low pick-up rate and hence, 
poor cost effectiveness [3-6]. They advocate in favour of staging bone 
scan in stage III or IV breast cancers. Bone scan results can be of 
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prognostic value. Few studies reported that patients with baseline 
positive bone scans are more prone for skeletal relapse subsequently 
[6,7]. Various studies in the past have reported positivity of bone 
scans in clinical stage I carcinoma breast ranging from 0-18% and that 
in stage II upto 0-41%[3]. Bone scans also cannot predict which of the 
patients in stage I or II of breast cancer will ultimately develop 
skeletal metastases. With refinement in imaging techniques, bone scan 
positivity has significantly reduced in T1 & T2 breast cancers. 
 Present study is being done to assess the usefulness of bone scan 
as a staging investigation in early breast cancer. 
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AIMS & OBJECTIVES 
 
To identify the utility of baseline bone scans in early breast carcinoma 
by studying its:- 
 
•  impact on initial treatment decision 
 
•  Positive Predictive value 
 
• usefulness as a baseline test for future comparisons 
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MATERIAL & METHODS 
 This study was done in the Department of Surgical oncology of 
Cancer Institute after the approval of ethical committee. 
Study Design:  This is a retrospective observational study of all stage 
I & II breast cancer patients who had baseline bone scan & were 
treated at the institute between the years 2000 to 2004 and followed 
up for 10 years. 
Inclusion Criteria:  All new breast cancer patients with cT1/T2 & 
N0/N1tumors, according to AJCC (7
th
 edition) indexed between 
2000–2004 and undergoing a baseline bone scan were included. 
Exclusion Criteria: 
• Patients with cT3/T4 or cN2/N3 tumours.  
• Patients presenting after surgery, done elsewhere, for breast 
lump (Lumpectomy/Excision biopsy/mastectomy) 
• Patients with early breast cancer, not undergoing a baseline bone 
scan test.  
• Patients not completing the planned treatment. 
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Primary End Point: Positive predictive value of Bone Scan 
Secondary End Point: Overall Survival / Disease free survival. 
Material & Methods:  Case records of all the early breast cancer 
patients who were treated at the institute between Jan1, 2000 to Dec 
31, 2004 were studied for the pattern of bone scan uptake. Patients 
had a preoperative baseline bone scan performed 3-4 hours after 
injection of 25mCi of 99mTc-labeled methylene diphosphonate. All 
scans were reported by a nuclear medicine consultant. Plain 
radiographs/CT or both were taken of areas of increased tracer uptake. 
The criteria for considering a bone scan as positive was that if 
complimentary imaging studies like plain x-rays or CT scan were 
confirmatory for the site of uptake in bone scan or in due course of 
time, patient relapses in the site of initial bone scan uptake.Patients 
were regularly followed-up, and the time and site of any relapse was 
recorded. The AJCC TNM system (7
th
 Edition) for clinical staging 
and tumoursize (T) was used. 
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REVIEW OF LITERATURE 
 
 Breast Cancer poses a major public health problem throughout 
the world for women. The age specific incidence rates for breast 
cancer increases with age.  
 In India, according to the tumour registries of all the metros, 
breast cancer is the most common cancer in women. According to 
Madras Metropolitan Tumour Registry (MMTR)[8], the Crude 
incidence rate (CIR) & Age standardised rate (ASR) of carcinoma 
breast was as follows: 
MMTR 1982-87 2000-05 2006-10 
Carcinoma 
Breast  
CIR 14.4 28.0 34.2 
ASR 19.1 30.5 33.9 
 
In Delhi, Mumbai & Kolkata the Age adjusted rates were 32.3, 
30.1 & 25.5 respectively in the year 2006-08. 
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 It is also the most common cancer diagnosed in women in 
United States and the second most common cause of cancer death. In 
2006, about 274,900 new cases of carcinoma breast were diagnosed in 
United States and about 40,970 patients died due to this cancer. 
Incidence rates across the world can vary up to four fold, ranging 
from 27/100,000 in eastern Asia & middle Africa to 96 in west 
Europe [9]. Breast cancer was also the most common cancer in 
Europe in 2006, accountingfor 13.5% of all new cancers [10]. 
 The lifetime risk for breast cancer in United States is 1 in 8 
women. The risk at the age of 40 years is 1 in 250 and that at 60 years 
accounts to about 1 in 35 women. Breast cancer not only ranks first 
among cancer deaths in women in less developed regions (14.3%), but 
also the second cause of cancer death in more developed regions 
(15.4%), just behind carcinoma lung [9]. 
According to the hospital cancer registry-Cancer Institute (WIA), the 
proportion of breast cancer patients was 15% of total cancer patients 
registered in the year 1984-88. This percentage increased to 23.2% 
during 2005-06 and was static at 23.2% in 2009-10 also [11]. 
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The stage wise distribution of breast cancer is as follows 
Stage 1980-1989 2003-2007 
No. % No. % 
I 30 1.4 66 2.1 
II 447 21.3 1018 32.2 
III 908 43.2 1474 46.6 
IV 454 21.6 330 10.4 
SNP 262 12.5 274 8.7 
Total 2101 100 3162 100 
 
 Thus, the percentage of early breast cancer patients (stage I & II) 
has increased from about 22.7% in the early 80’s to about 35% in 
2010. The SEER data 1990 also suggest an increase in stage I breast 
cancer from 25% to about 50% of the invasive cancers from the year 
1983 to 1990. 
Since 1990, the breast cancer death rates have reduced significantly, 
both in US (decreased by 24%) and other countries [12,13].This can 
be attributed to widespread use of screening mammograms and the 
introduction of better adjuvant chemotherapy and use of tamoxifen. 
10 
 
 Due to its high prevalence and prolonged course, breast cancer 
has always been a favoured topic for study. As early as the last decade 
of 19
th
 century, Halstead described breast cancer as a localised disease 
at presentation that spread contiguously in an orderly manner directly 
via the lymphatic spread, first to axillary nodes and then to distant 
sites. He proposed that even vertebral or abdominal metastases are 
also due to contiguous lymphatic spread and thus a radical surgery can 
halt the spread of breast cancer by removing all the localised disease. 
This concept remained unchallenged till the mid-20
th
 century when Dr 
Bernard Fisher proposed the systemic theory stating that carcinoma 
breast is a systemic disease from the time of presentation. The axillary 
Lymph nodes are also an indicator of distant spread and thus, a radical 
surgery or any other local treatment is unlikely to improve overall 
survival. This paved way for modified radical mastectomies and later 
on breast conservation. A third hypothesis, known as the Spectrum 
theory, was put forth by Samuel Hellman in 1994 suggesting 
carcinoma breast as heterogeneous diseaseconsisting of a spectrum of 
proclivities with localised disease at one end and metastatic disease on 
the other end. He proposed that lymph node metastases suggest a 
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more virulent biology of the tumour and thus high propensity for 
distant metastases.  
EARLY BREAST CANCER (EBC): 
 Early breast cancer involves tumour in the breast measuring not 
more than 5cm with or without discrete lymph nodes in the axilla. 
This consists of stagesIA,IB,IIA& IIB of AJCC staging for carcinoma 
of breast (7
th
 Edition). 
 Tubiana et al [14-16], at Institute Gustave-Roussy, studied 3000 
breast carcinoma patients before the advent of routine adjuvant 
chemotherapy and showed that metastatic potential & tumour grade 
was directly proportional to the size of primary tumour.  
 A series from MSKCC [17] analysed T1N1 & T1N0 breast 
cancer patients presenting to them between 1965 & 1970 and found 
that amongst the node negative patients, 12% patients with tumour 
<1cm recurred and the recurrence rate was 26% in patients with 
tumour size between 2-3cm. Thus, about 88% patients with tumour 
size <1cm could be treated effectively with loco-regional treatment 
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alone. Another analyses from Chicago suggested 79% cure rates with 
loco regional therapy in patients with node negative T1 lesions. 
 In patients with positive axillary nodes, the number of nodes 
involved is a major indicator of prognosis. In the same MSKCC series 
mentioned above [17], loco-regional therapy was curative in 68% of 
patients with T1 tumours and 1-3 axillary nodes positive. The Chicago 
series also reflected same results. The survival was unchanged if only 
1 node was involved in patients withT1 tumours. Even with 2 or 3 
nodes being positive, 73% patients with T1 lesion were alive after a 
follow up of 20 years without any relapse.  
 As discussed, early breast cancer generally has an excellent 
prognosis with treatment. The 5yr overall survival for stage I breast 
cancer can be upto 88% & for that of stage IIA is about 81% [18]. 
However, as a result of improved diagnostic techniques & newer 
therapeutic options, survival rates are expected to improve.  
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CARCINOMA BREAST & BONE METASTASES 
 Bone health & its maintenance has become an integral part of 
the multimodality treatment of breast cancer. Bone is the commonest 
distant metastatic site in carcinoma breast. It is estimated that of all 
the metastatic breast cancer, about 47 to 85% will have bone 
metastases [19]. Common bones which have a prelidiction for 
metastases include spinal column (especially lower dorsal 
vertebrae),pelvis,ribs,skull and long bones because of the presence of 
highly vascular red marrow [20]. Typically, skeletal metastases have 
both osteolytic&osteoblastic components, with preponderance of 
osteolytic component [21]. Even in pure osteolytic appearing lesions, 
there is an associated osteoblastic component which is responsible for 
increased radionuclide uptake in bone scan and detection of 
metastases. Pure lytic lesions can be missed on bone scan. 
Normal Bone Remodelling- The bone micro-environment: 
Besides protecting the vital organs and providing support, bone acts as 
reservoir of various growth factors & calcium, phosphorus which are 
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released during the process of bone remodelling. The bony skeleton is 
always undergoing remodelling. There is a balance between the bone 
forming & resorption process. Remodelling of bone is described as a 
cyclic process starting with bone resorption and ending with 
deposition of bone.Cells involved in the process are osteoclasts, the 
bone degrading cells and osteoblasts,the bone forming 
cells.Mesenchymal stem cells give rise to cells belonging to 
osteoblastic lineage, which include osteocytes,bone lining cells and 
osteoblasts. Bone lining cells are relatively undifferentiated cells 
which line the bone. Exact function of these cells is unclear. Their 
retraction is required to start the process of bone resorption [22]. 
 Osteoblasts produce the macrophage colony stimulation factor & 
Receptor Activator of Nuclear Factor kB ligand (RANKL) which 
attaches themselves to their respective receptors,i.e, f-cms& RANK 
on the precursor osteoclast cells and activate their differentiation. 
Osteoblast cells also produce osteoprotegrin (OPG) which binds to 
RANKL by acting as a decoy receptor for them and thus prevents 
activation of osteoclasts. Thus,the ratio of RANKL and OPG 
determines the degree of osteoclastic activity. The activated 
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osteoclasts then attaches to the surface of the bone and creates a 
resorption lacuna where in proteolytic enzymes like cathepsin K and 
other acids are released and causes degradation of bone matrix. In 
response, the preosteoblasts are recruited to the site of bone resorption 
and get differentiated into mature osteoblasts,which then produce 
osteoid consisting of chondroitin sulphate,collagen,osteonectin& other 
non-mineral molecules which mineralize over several months [23]. 
Bone microenvironment in presence of skeletal metastases: 
The breast cancer cells reach the bone via haematogenous spread,most 
commonly to the vertebral bodies via the Batson's prevertebral venous 
plexus. Once within the bone micro environment, these cancer cells 
produce several growth factors,most important of them is the 
parathyroid hormone related protein (PTHrP) [24]. PTHrP can cause 
up regulation of RANKL and down regulation of OPG [25], causing 
osteoclast activation and bone resorption. Other growth factors which 
are stored in the matrix are also released,such as transforming growth 
factor-B (TGF-B), insulin like growth factors (IGF's), vascular 
endothelial growth factor (VEGF), fibroblast derived factors and 
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calcium. These growth factors can cause stimulation & proliferation 
of tumour cells leading to more production of growth factors &PTHrP 
and thus,in turn,more degradation of bone matrix and perpetuation of 
the metastatic cycle. Various cytokines like IL-6,IL-8,IL-11 are also 
secreted by tumour cells and cause differentiation of osteoclasts and 
bone resorption. 
Natural History of Bone Metastases:  
 It is estimated that among the patients with breast & prostate 
cancer who develop distant metastases, about 65-75% will eventually 
develop metastases in bone [26,27]. Patients of breast cancer with 
bony metastases are more prone for skeletal complications. 
Carcinoma breast patients with skeletal metastases have a prolonged 
median survival of about 24-30 month, which renders them more 
susceptible to develop skeletal related events (SRE)[28]. These 
include pathological fractures of the involved bone, spinal cord or 
nerve root compression (due to pathological fracture or vertebral 
instability),hypercalcemia of malignancy, need of radiotherapy for 
symptomatic bone lesions and surgery for impending fractures. 
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Hypercalcemia of malignancy can be associated with renal 
failure,altered mental status or even death. Without bisphosphonate 
therapy, about 3-4 SRE’s can occur in these patients every year [28]. 
Various factors determine the risk of SRE in patients with bone 
metastases. These are (a) NTX: N-terminal telopeptide of type I 
collagen, which is a reliable marker of resorption of bone (b) Number 
of baseline bone lesions (more than 3 lesions are associated with 
higher rate of skeletal morbidity) (c) Presence of pain with baseline 
bone lesions. Site of metastatic lesions within the skeletal system also 
determines patient’s risk of developing skeletal related event. 
Metastases in spine, pelvis or chest are associated with higher risk as 
compared to those limited to appendicular skeleton or skull. However, 
median overall survival was the same irrespective of the site of bone 
uptake. 
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Treatment Modalities for Skeletal Metastases: 
Local Therapy 
1.Radiation: Most of the treatment strategies in case of bone 
metastases are palliative in nature and aim at symptomatic relief. 
Many of the metastatic bone lesions are subjected to external beam 
radiotherapy as this will cause relief of pain and other symptoms by 
more than 70%[29]. 
Systemic Therapy 
1.Bisphosphonates: 
Due to predominant lytic nature of the bone metastases secondary to 
breast carcinoma, most of the attention was to inhibit osteoclast 
mediated bone damage.Since many years, bisphosphonates were the 
standard of care in treatment of bone secondaries.  Bisphosphonates 
are the compounds having a structure resembling inorganic 
pyrophosphate (PPi). Bisphosphonates have characteristic two carbon-
phosphate bonds (Pi-C-Pi) that makes them highly resistant to 
hydrolysis secondary to the action of enzyme phosphatase. Both 
bisphosphonates and pyrophosphates selectively bind to the crystals of 
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hydroxy apatite within the bone and thus concentrate at active bone 
remodelling site. These compounds are then ingested by bone 
destroying osteoclast cells causing them to undergo apoptosis & thus, 
prevent loss of bone mass [30]. 
 Bisphosphonates are of two types: Nitrogen containing & Non 
Nitrogen containing. The examples of non-nitrogen containing 
bisphosphonates are Etidronate, Tiludronate&Clodronate and that of 
nitrogen containing are Pamidronate, Olpadronate, Ibandronate, 
Risedronate&Zoledronate. These nitrogen containing bisphosphonates 
bind to & blocks an enzyme known as Farnesyl diphosphate synthase 
(FPPS) functional in  3-hydroxy-3-methyl-glutaryl-CoA reductase 
(HMG-CoA reductase) pathway, leading to inhibition of downstream 
metabolite formation (geranylgeraniol&farnesol) which maintains 
cytoskeletal stability. Thus, the osteoclasts undergo apoptosis after 
ingestion of these diphosphonates bound to the surface of bone [31]. 
 Only intravenous pamidronate&zoledronate have been approved 
by US FDA for use in patients with carcinoma breast &bone 
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metastases. Europe has approved oral & IV ibandronate and also oral 
clodronate for use in these patients. 
 IV Pamidronate: Two randomised, multicentre, placebo 
controlled trials established the safety & efficacy of intravenous 
pamidronate [32,33]. In each trial, pamidronate was shown to cause 
decrease in the incidence & onset of skeletal related events (SRE) 
{SRE was defined as spinal cord compression, pathological fracture, 
requirement of radiation for bone pain or surgery for 
treatment/prevention of fracture}. Pamidronate was associated with 
(a) reduction in the proportion of patients having more than 1 SRE 
(51% as compared to 64% in placebo arm) (b) median time for 
development of first SRE being extended by 6 months (12.7 months 
vs 7 months) (c) reduction in the rate of mean skeletal morbidity (2.5 
vs 4.0 SRE per year) [34] 
 IV Zoledronic acid: The effectiveness of zoledronate in 
decreasing the SRE risk in patients with breast carcinoma was far 
more when compared to pamidronate [35-37], about 20% additional 
over what is achieved by using pamidronic acid (p=0.025). 
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 Bisphosphonates are generally tolerated well. They can cause 
jaw osteonecrosis, twice more commonly in the mandible than in 
maxilla. This is secondary to prolonged intravenous use in cancer 
patients. Bisphosphonates can, very rarely, cause alteration in renal 
function. Less than 1% of breast cancer patients, who had received 
zoledronic acid for up to 2 years, had severe elevation in serum 
creatinine levels [35]. As the onset of SRE’s can cause fall in the 
quality of life (QOL) of the patients, bisphosphonates also have a 
favourable impact on the QOL of breast cancer patients. 
 Research is now on to study the direct antitumor effect of 
bisphosphonates, mainly zoledronic acid. It is proposed that along 
with chemotherapy, bisphosphonates have a synergistic effect on the 
tumour in breast cancer patients, causing decrease in burden of 
tumour in the skeleton by causing death of tumour cells [38,39]. They 
may also delay or even prevent bone metastases in early breast cancer 
patients. 
2. Denosumab: It is a human monoclonal antibody to RANK Ligand 
that binds to RANKL and prevent it to activate the precursor 
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osteoclasts. In a clinical trial by Stopeck[40], denosumab was found to 
be superior as compared to zoledronate in preventing skeletal related 
events in breast,multiple myeloma and prostate cancer patients. FDA 
has recently approved this drug for treating osteoporosis in women 
having high risk of fractures. 
3.Teriparatide: This drug, the amino-terminal 34 amino acid of 
parathyroid hormone, acts on osteoblasts and stimulates formation of 
bone. However, its use can cause increase in the incidence of 
osteosarcoma and exacerbation of skeletal metastases due to its bone 
turnover effect[41]. 
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BONE SCAN 
 Bone scans are commonly used to screen the skeletal system for 
detection of bone metastases in patients with cancer. A minimum of 
50% decalcification should occur before a bony lesion is visible on a 
plain x-ray. However, bone scan can detect the same lesion with 
decalcification as little as about 10-15%. Bone scintigraphy and 
conventional radiology are complementary to each other. Alterations 
in mineral content of the bone leading to anatomical changes are 
demonstrated by radiographs whereas bone scintigraphy reveals the 
changes in metabolic status secondary to alteration in osteoblastic 
activity & vascularity of bone. 
 In cases where bone scan suggests metastases but the plain x-ray 
of the region of interest is normal, there is high possibility of the x-
rays becoming abnormal within 12 to 18 months. Up to 75% of the 
lesions picked up by bone scan will develop corresponding 
radiographic changes by the end of 6 months. Strender et al found that 
8% of breast cancer patients with normal baseline bone scan will 
eventually develop metastases in bone. Corresponding proportion 
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after 36 months was nearly 15% [42]. The chances of malignancy in 
bone scans with solitary rib uptake is less than 50% while it increases 
to 68% if the solitary uptake is noted in axial skeleton. 
 After the introduction of PET CT, its use has greatly increased 
as a staging tool, more commonly in patients with some uptake in 
baseline bone scans. Studies have shown that the sensitivity of PET 
CT is similar to that of bone scan but it is much more specific. The 
sensitivity of PET CT and conventional imaging (including 
CT/USG/Scintigraphy/X-rays) was 97.4% vs 85.9% respectively 
(p=0.009) while the specificity of these two modalities was 91.2% vs 
67.3% (p=<0.001) [43]. When compared to bone scan, PET CT better 
detects osteolytic lesion while bone scan is superior in detection of 
osteoblastic lesions. Ohta et al studied bone scan and PET CT in 
detection of bone metastases in patients with breast carcinoma and 
found that the accuracy, sensitivity and specificity of PET CT was 
94.1%, 77.7% & 97.6% respectively while it was 80.3%, 77.7% & 
80.9% respectively for bone scan [44]. 
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 As mentioned above, conventional imaging is complementary to 
bone scan and any suspicious uptake in the bone scan should be 
confirmed using imaging like CT/MRI or PET-CT. If there is 
associated cortex breach & the site is easily accessible, then a guided 
or open biopsy can be considered for confirmation of metastatic 
nature of the lesion.  
 In the past, various agents have been used for the performance 
of radionuclide bone scans such as strontium-87, Gallium-67, 
Fluoride-18 and Thallium-201. A new agent for imaging of bone, 
known as 99m Technetium labelled stannous tripolyphosphate, was 
introduced in 1971 by Subramanian and McAfee. Gradually, 
Methylene diphosphate (MDP) &hydroxy methylene diphosphate 
(HMDP) became the most commonly used agents for bone 
scintigraphy. The reason for their popularity was rapid clearance from 
the blood stream & higher affinity for skeletal system. After these 
agents are injected intravenously, they are distributed in the 
compartment of extra cellular fluid. Bone accumulates a major 
proportion of the dose injected (about 58% of the MDP after 1 hour of 
injection) and the remaining gets excreted in the urine. Multiple 
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factors govern the uptake of these tracer agents into the bone, such as 
changes in flow of blood or capillary permeability, increased surface 
area of the bone and formation of reactive new bone. Majority of 
pathological events, including fracture, infection or metastases, 
initiate an osteoblastic response leading to increased uptake of tracer 
agent. 
Indications of Radionuclide Bone Scan: There is a wide range of 
indications for bone scan extending in the fields of orthopaedics, 
sports medicine & rheumatology. Major indications in oncology are 
listed below: 
1) To screen patients having cancers that are prone for metastatic 
spread to bones (e.g. lung, kidney, breast or prostate cancers) 
2) To further evaluate suspicious skeletal radiographs 
3) To assess viability of bone as in cases of vascularised free bone 
grafts 
4) Response of the skeletal system to various therapies like 
chemotherapy or radiotherapy can be assessed using serial 
bone scans 
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5) To assess the nature of bone involvement- monostotic or 
polyostotic. 
6) To localize sites for obtaining biopsy. 
7) To know the extent of primary bone tumour.  
Procedure of Bone Scan: 99m Tc-MDP is used in a dose that varies 
as per the policy of the department. Usually, the dose ranges from 20-
30 mCi (740 – 1110 MBq). In our institute, we administer 25 mCi of 
the tracer and images are obtained after 3-4 hrs of injection. The 
equipments required are a scintillation camera and a single/dual head 
whole body collimator. In cases where a localised pathology is 
suspected (e.g osteomyelitis) or the bone viability is in question, 3 
phase bone scans are performed. Different phases of bone scan are: 
1) Dynamic Flow phase: The agent in injected with the patient 
under the gamma camera and images are obtained every 3-5secs 
for 1 minute. 
2) Blood Pool phase: Images are obtained with 2,00,000 to 
5,00,000 counts for the evaluation of degree of vascularity in 
the region of interest. 
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3) Static View Phase/Delayed phase: Images obtained after 2-4 
hours of injection 
4) Sometimes images are also obtained after 24 hours of injection 
& this is known as the fourth phase. 
Normally, approximately 50% of the injected dose of tracer gets 
localized within the bone and the remaining 40-50% is excreted via 
the kidneys into the urine. Hence, the kidneys & urinary bladder are 
visualized in most of the scans. In cases with extensive bone 
metastases where most of the tracer is taken up by the metastatic 
lesions and nothing gets left behind for the kidneys to excrete, the 
kidneys & bladder are not visualized & such scans are referred to as 
Super scan. 
Precautions to be taken while performing the scan:  
1)  Though the radiation exposure with bone scan is minimal to the 
patient, universal precautions should be taken by the health care 
professional performing the scan. 
2) Patients should be encouraged to drink plenty of fluids during 
the waiting period after injection of the agent. This will reduce 
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the back ground activity by decreasing the soft tissue uptake of 
the agent and improving renal excretion. 
3) Patients are advised to void immediately prior to image 
acquisition, so that the urinary bladder is emptied and pelvic 
bones are not obscured. 
4) Any attenuating material like belts, buckles, keys or badges 
should be removed from the region of interest. 
5) In cases of painful bony metastases, adequate analgesia should 
be ensured so that patient can lie down for image acquisition & 
movement artefacts can be minimized. 
A complete history & the relevant clinical details should be 
known before interpreting a bone scan. Areas that normally 
show uptake in a bone scan are the epiphyseal growth plates & 
joints (depending upon the age and metabolic status of the 
patient).  Children may show uptake in skull suture lines at the 
time of their closure, but it becomes normal once the sutures are 
closed. Purely osteolytic lesions like Eosinophilic granuloma & 
Multiple myeloma are not picked up by bone scan. 
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RESULTS 
1. AGE DISTRIBUTION 
S.No Age Group 
(Years) 
No. of 
Patients(%)  
No. of patients with 
Bone Scan uptake(%) 
1 < 20 0 (0) 0 (0) 
2 20 – 29  1 (0.36) 1 (0.89) 
3 30 – 39  39 (14.02) 9 (8.03) 
4 40 – 49  82 (29.50) 22 (19.64) 
5 50 – 59  88 (31.65) 43 (38.40) 
6 60- 69  48 (17.27) 26 (23.21) 
7 70 – 79  17 (6.11) 9 (8.03) 
8 80 – 89  3 (1.08) 2 (1.78) 
9 TOTAL 278 (100) 112 (100) 
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 Incidence wise, 61% of the total study population was between 
40-59 years of age. However, patients between 50-69 years of 
age constituted about 61% of the total patients with positive 
baseline bone scan. Patients on either extreme of age, i.e, <30 
years and >70 years constituted only 0.9% & 9% respectively. 
 
2. SEX DISTRIBUTION 
S.No Sex No. of patients 
(%) 
1 Female 275 (98.92) 
2 Male 03 (1.08) 
3. TOTAL 278 (100) 
 
 
 
 Almost 99% of the study population were females. Males 
constituted only 1.08% of all the early breast cancer patients 
studied. 
 
 
Male: 
1.08%
Female: 
98.92%
Male
Female
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3. DISTRIBUTION OF BONE SCAN UPTAKE 
S.No Uptake No. of patients (%) 
1 Present 112 (40.29) 
2 No Uptake 166 (59.71) 
3. TOTAL 278 (100) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 About 40% of total patients with early breast cancer in the 
study showed an uptake (hot spot) in the baseline bone 
scan while about 60% patients have normal baseline bone 
scans. 
 
40.29%
59.71%
Uptake present
No Uptake
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4. NUMBER OF BASELINE BONE SCAN UPTAKE 
S.No Uptake No. of patients (%) 
1 Single site 55 (49.10) 
2 Two sites 34 (30.36) 
3 Multiple sites 23 (20.54) 
4 TOTAL 112 (100) 
 
 
 
 
 
 
 
 
 
 
 
 79.46% of the patients had uptake in one or two sites on 
baseline bone scans, while only 20% showed multiple sites 
of uptake. 
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5. SITE DISTRIBUTION OF BASELINE BONE SCAN  
S.No. Site of uptake No. of 
Patients  
Percentage (n=112) 
1 Skull 06 5.38 
2 Sternum 03 2.68 
3 Scapula 10 8.93 
4 Cervical Vertebra 01 0.89 
5 Dorsal Vertebra 17 15.18 
6 Lumbar Vertebra 62 55.38 
7 Sacrum / S.I Joint 19 16.96 
8 Ribs 29 25.89 
9 Pelvic Bones 11 9.82 
10 Humerus 01 0.89 
11 Radius / Ulna 0 0 
12 Femur 11 9.82 
13 Tibia / Fibula 02 1.78 
14 Clavicle 02 1.78 
TOTAL PATIENTS 112 100 
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 72.34% of the patients had an uptake in the lumbo-sacral 
region, on initial bone scan. Taking rib uptake into 
consideration, along with lumbo-sacral uptake, includes 
98.23% of the patients (with or without uptake in other 
sites). Uptake in the appendicular skeleton was seen in 
12.50 % of the patients. 
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6. CAUSES OF BASELINE BONE SCAN UPTAKE 
S.No Cause of Uptake No. of  
Patients 
Percentage 
(n=112) 
1 Osteo-arthritic 
changes 
13 11.60 
2 Spondylosis 12 10.71 
3 Osteoporosis 10 8.93 
4 Spondylolisthesis 4 3.57 
5 Degenerate 
Changes 
4 3.57 
6 Lytic lesion 1 0.89 
7 Osteoid Osteoma 1 0.89 
8 Paget’s disease 1 0.89 
9 Polio 1 0.89 
10 Road accident 1 0.89 
11 Normal 47 41.96 
12 No Imaging done 26 23.21 
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7. NUMBER OF BASELINE COMPLEMENTARY IMAGING 
DONE 
S.No Type of Imaging No. of 
Patients 
(%) 
No. of Patients 
with Malignant 
lesions 
1 Plain X-rays  53 (47.3) 0 
2 CT/MRI 27 (24.1) 0 
3 Both x-rays & 
CT/MRI 
06 (5.3) 0 
4 None 26 (23.2)  
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 86 out of 112 patients (76.78%) with baseline positive bone 
scan underwent complementary imaging tests for 
confirmation of site of uptake. 59 patients underwent single 
or multiple plain x-rays and 33 patients underwent CT or 
MRI of the site of bone scan uptake. Incidentally, none of 
the imaging confirmed metastases in any of the uptake in 
baseline bone scans. Chest x-ray in one patient, with bone 
scan uptake in right 5
th
 rib, revealed lytic lesion but it was 
kept under observation and patient did not progress in the 
follow up period.   
 
47.3%
24.1%
5.3%
23.2%
Plain Xrays CT/MRI Both None
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8. RELATION OF TUMOR SIZE (T Status) WITH BONE SCAN 
UPTAKE 
 
S.No T Status No. of 
Patients (%) 
Patients with Bone scan 
uptake (%) 
1 T1  25 (9.00) 11 (9.82) 
2 Small 
T2 
97 (34.90) 35 (31.25) 
3 Large 
T2 
156 (56.10) 66 (58.93) 
4 TOTAL 278 (100) 112 (100) 
 
Bone scan & size Cross tabulation 
 
 
SIZE 
Total T1 SmallT2 LargeT2 
Baseline 
Bone 
scan 
 
Uptake 
+ 
Count 11 35 66 112 
% within size 44.0% 36.1% 42.3% 40.3% 
Uptake 
- 
Count 14 62 90 166 
% within size 56.0% 63.9% 57.7% 59.7% 
Total Count 25 97 156 278 
% within size 100.0% 100.0% 100.0% 100.0% 
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9. RELATION OF TUMOR SIZE WITH SITE OF PROGRESSION 
S.No. T Status No. of 
Patients 
with 
progression 
(%) 
Site of 
Progression 
No. 
of 
sites  
Patients 
with 
positive 
baseline 
Bone scan  
1 T1 5 (20) Skeleton 0 0 
Visceral 4 3 
 Others 4 
11
35
66
0
20
40
60
80
100
120
140
160
180
T1 Small T2Large T2
No Bone scan uptake Bone scan uptake
25
97
156
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2 Small 
T2 
16 (16.50) Skeleton 7 7 
Visceral 13 
Others 6 
3 Large 
T2 
39 (25) Skeleton 10 18 
Visceral 32 
Others 9 
 TOTAL 60 (21.58)  85 
sites 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ‘Others’ include relapse in the loco-regional sites, opposite 
breast or in mediastinal nodes 
39
5
16
LARGE T2 T1
SMALL T2
7
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6
4
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32
9
SKELETON
VISCERAL
OTHERS
PROGRESSION
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 For analyses T2 was divided into small T2 (more than 2 cm 
but not more than 3cm) and large T2 (more than 3 cm but not 
more than 5cm). 
 T1 comprised of 9% of the study group and about 44% of 
these patients had a positive base line bone scan. Out of these 
11 T1 patients with positive base line bone scan, none 
progressed in the skeletal system during the follow up period. 
5 patients (20%) progressed during follow up, 4 had visceral 
metastases and 1 failed in the loco regional site.  
 Small T2 comprised almost 35% of the study population with 
36% of these showing uptakes in base line bone scans. 16.50% 
of the small T2 population progressed over time. 7 Patients 
failed in the skeletal system (2 exclusively in bones and other 5 
had coexisting visceral/loco regional disease). Of these 7 
patients failing in the skeletal system, 4 had positive baseline 
bone scans, one of the scans showing uptake in the site of final 
progression (which was initially kept under observation). The 
other three bone scans had uptake in sites other than the site 
ofprogression. 
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 Large T2 consisted of about 56.10% of the total patients 
studied with about 42% of these having positive baseline bone 
scan. 25% of the large T2 patients progressed over time. 10 
patients progressed in the skeletal system (7 exclusively in 
bone and 3 had coexisting visceral metastases). Of these 10 
patients, 4 had initial bone scan positive and other 6 had 
normal baseline bone scans. Of the 4 patients with positive 
base line bone scans, 1 did not have any follow up bone scan 
and skeletal metastases in the site of initial bone scan uptake 
(along with liver metastases) were detected on CT scan in the 
follow up period, 1 had initial uptake in a site other than the 
site of ultimate progression. Other two patients had initial 
uptake that correlated with the site of final progression. 
Thirty two patients had visceral metastases, with or without 
skeletal/loco regional metastases. Of these, 14 patients hadan 
uptake in the baseline bone scan which did not progress over 
time. 
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10. FOLLOW UP BONE SCANS / IMAGING 
 Baseline Bone Scan Positive 
(n = 112) 
Baseline Bone Scan 
Normal (n = 166) 
Follow up BS Comp. 
Imaging 
Follow up BS Comp. 
Imaging 
Not  
done 
74 Not  
done 
97 Not 
done 
129 Not 
done 
156 
No uptake 9 WNL 07 Static 25 WNL 4 
Improved / 
Static 
14 Positive 08 Positive 6 
Progressed 15  Progressed 12  
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11. Relation between uptake in baseline bone scan and skeletal 
progression over follow up. 
 
 
 
 Hence, the true positivity of bone scan was = 3.57% 
 Of the 4 true positive bone scans, the initial tumour size was 
small T2 in one (2.5cm) and large T2 in other 3 patients 
(4cm,4.5cm & 5cm). 
 Of these 17 patients with skeletal progression, 10 patients have 
expired and 7 are alive with disease. 
 
Corelation of 
baseline uptake with 
site of progression
BASELINE 
BONE SCAN 
STATUS
Total Patients 
failing in 
skeletal system
17
Positive
(n=8)
Corelated
(n=4)
Did not 
corelate
(n=4)
No uptake
(n=9)
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12. DATA OF TRUE POSITIVE PATIENTS 
 
 Age 
(Yr) 
Sex Size  
Of 
Tumor 
N 
Status 
Meno- 
Pausal 
Status 
ER Baseline 
Bone 
Scan 
Year Imaging 
(Xray/ 
CT/MR) 
1 50 F 5cm cN1 Post + L4,5,S1 2000 Not done 
2 47 F 4.5cm cN1 Pre - L5 2002 x-ray 
WNL 
3 54 F 2.5cm cN0 Post-
Hyst 
- L5 2001 CT scan  
WNL 
4 67 F 4cm cN1 Post + D11,L2-
5,Rt 
Femur 
(h/o TB 
Spine) 
2003 CT Scan  
No Lytic 
Areas 
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 Repeat 
Bone 
Scan 
Imaging Year Rx 
Given 
Further 
Bone 
Scan 
Last 
Follow 
Up 
Status 
1 Pelvic 
bones 
 
CT s/o LS 
spine & 
Liver mets 
2001 Palliative 
RT 
Not 
Done 
May’02 Lost 
to 
Follow 
up 
2 L5 PET s/o Left 
Humerus, 
Lumbar 
vertebra 
mets 
2009 RT / 
Zoledronic 
Acid / 
Oral 
Chemo 
2011: 
Progressive 
Disease 
July’13 Alive 
With 
Disease 
3 D-L 
Vertebra 
CT s/o Spine 
& Liver 
mets 
2008 Zoledronic 
Acid / 
Oral 
Chemo 
Not Done Sept’11 Expired 
4 Progression MRI s/o 
Mets in 
D11,L4-5 
& Femur 
2009 RT /  
Zoledronic 
Acid 
2011: 
Progression 
Received 
Samarium 
Dec’12 Expired 
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DISCUSSION 
 Ours is a study of patients with early breast cancer (stage I & II) 
who underwent baseline radionuclide bone scans as a part of 
metastatic work up. We intend to study how useful these bone scans 
proved during the treatment and long term follow up of the patients. 
 Following factors were studied: Age of the patient at 
presentation, menstrual status, Estrogen receptor status, clinical stage 
of cancer based on tumour size (cT status), nodal status (cN0 or cN1) 
and the cause & distribution of baseline bone scan uptake. 
 Regarding patient characteristics included in our study, almost 
99% of the patients were females. The most common age group as far 
as incidence is concerned, was between 40-59 years of age, which 
comprised of about 61% of the study population. This was in 
concordance with a study by Mitsuru Koizumi et al [45] who studied 
the benefit of baseline bone scans across all stages of breast cancer. 
The age group between 40-59 years constituted about 65% of all the 
patients. However, 61.6% of the patients in age group of 50-69 years, 
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in our study, had uptake in baseline bone scans, making it the most 
common age group with respect to uptake in baseline bone scans. 
Our study had 38.5% premenopausal & 46% postmenopausal women. 
This was not very much different from that of Mitsuru Koizumi et al 
[45] where it was 49.3% & 49.8% respectively. Around 15% of our 
patients had hysterectomy done in the past due to several benign 
causes & hence their menopausal status could not be ascertained. The 
percentage of ER positive, ER negative & ER status unknown patients 
in our study also correlated with previously quoted study [45] (35.9%, 
33.4% & 30.6% vs 37.2%, 31% & 31.6% respectively).  
 The assessment of data regarding nodal status revealed that our 
cN1 rate was greater than that reported in Japan [45] (61.87% vs 
42.8%). Most of the studies of utility of bone scan in breast cancer 
were done more than 15 years ago [45-48]. These studies considered 
bone scan as true positive when the site of uptake in the initial bone 
scan was confirmed by a complementary imaging test (plain x-
ray/CT/MRI). In our study, none of the uptakes in 86 of 112 patients 
could be confirmed by imaging tests (26 patients did not undergo any 
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further imaging after bone scan). 47.3% of the baseline bone scan 
positive patients underwent multiple plain x-rays of the sites of 
uptake, 24% patients underwent either CT or MRI & 5.3% underwent 
both x-rays & CT/MRI. In a study by Yeh KA et al [47], 316 patients 
with carcinoma breast (cT1-2 lesions) underwent bone scans during 
metastatic work up & out of them 63 (20%) had suspicious or positive 
results on bone scan. This resulted in 101complementary imaging 
tests (80 plain x-rays, 10 CT scans & 11 MRI) & 4 biopsies. Only 7 
patients (2%) were confirmed to have skeletal metastases, most of 
them presenting with clinical signs of distant metastases. 
Thisindicatedthe extra burden on the cost of treatment due to the 
baseline bone scans. 
 As already discussed in observations, cT2 was divided into 
small and large T2 based on size (>2cm but not >3cm and >3cm but 
not >5cm respectively) as proposed by lagrange et al [49]. The 
proportion of T1, small T2 & large T2 in our study was 9%, 35% & 
56% respectively & in Japanese study [45], this was 40%, 34% & 
26%. Coleman et al [46] reported 30% & 70% T1 & T2 patients 
respectively. This shows that a considerable proportion of our early 
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breast cancer patients had T2 lesions (majority of which were large 
T2). It is well known that as the size of tumour increases, chances of 
bone metastases also increases. Incidence of bone metastases in stage 
I & II was 0.08% , 1.09% and 0%, 3% in the studies quoted earlier 
[45,46]. 
 The percentage of positive bone scans in Japanese study [45] 
was 0.23%, 0.55% & 2.26% in T1, small T2 & large T2 tumours 
respectively. Similar results were reported by Coleman et al, where 
there was 0.3% & 3% true positivity in T1, T2 lesions. This could not 
be directly compared to our study results as none of the imaging 
confirmed metastases in the baseline bone scan & true positivity was 
calculated based on skeletal relapse over prolonged follow up period. 
However, in our study also, 59% of patients with uptake in baseline 
bone scans belonged to large T2 group, reflecting the same results. 
Over a follow up of up to 10 years, 17 patients had skeletal 
progression, with or without other sites. Of the 4 patients who had 
progression in the sites corresponding to the uptake in baseline bone 
scan, 1patient belonged to small T2 group and 3 belonged to large T2 
group. Thus, 1out of 97 small T2 and 3 of the 156 large T2 patients 
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had true positive baseline bone scans, giving percentage positivity of 
1% & 1.92%, similar to that of studies mentioned earlier [45,46]. It is 
difficult to assign a cut off level of bone metastases beyond which 
routine bone scintigraphy can be recommended. As newer treatment 
modalities and targeted agents for bone metastases are becoming 
increasingly available, more and more bone secondaries can be 
treated, as a result of which, decision to get a bone scan done lies in 
the hands of treating physician or as per patient preferences. To help 
in this decision making, if it is assumed that bone scan can be avoided 
in patients with risk of bone metastases <1% & it should be done in 
patients with risk >3%, all our patients with T1 tumours & most of 
those with small T2 tumours would not have required a baseline bone 
scan. As the risk percentage in patients with large T2 was 2.26% , 3% 
or 1.92% in the different studies (including ours), these would fall in 
the ‘gray area’ where bone scan can be considered if associated high 
risk features are present, like node positive disease, high grade 
tumours or poor risk histology. Based on this, if bone scan is not 
required in patient with T1 or small T2 (3cm or less) tumours, about 
44% of baseline bone scans in our study could have been avoided. 
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 Samant R & Ganguly P [48] studied 250 breast cancer patients 
out of which 25 were detected with metastases at presentation. 
However, 23 of them had clinical signs or symptoms of distant 
metastases. Thus, bone scan was useful only in two patients in initial 
diagnosis of distant metastases. Low yield of baseline bone scan in 
asymptomatic patients with early breast cancer has also been reported 
in other studies [50,51] where the incidence of skeletal metastases at 
presentation was 5% in early breast cancer as opposed to 25% in 
advanced breast cancer [52,53]. 
 Many centres across the world, including ours, perform 
radionuclide bone scan in early breast cancer patients as a baseline for 
future comparison [45,46]. However, when we followed our patients 
who had uptake in baseline bone scans, 74 patients (66%) never 
underwent a follow up bone scan and thus the question of future 
comparison never arose. Nine patients (8%) had no uptake in follow 
up bone scans, i.e, the initial uptake disappeared. 15 patients (13.4%) 
had a worsened follow up bone scan report and 14 patients (12.5%) 
had improved/static report. Also, 97 patients (86.6%), of the ones with 
uptake in baseline scan, did not undergo any complementary 
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radiological imaging in the follow up period. 15 patients (13.4%) had 
a radiological imaging (plain x-rays or CT/MRI) of which 7 patients 
had normal imaging results (on comparing with bone Scan results, 5 
of them had progression, one had static disease & one had improved 
bone scan report). Out of the 8 patients with imaging suggestive of 
metastases, 7 had a progression and 1 showed improvement in the 
follow up bone scan. Thus it can be inferred that bone scan was useful 
as baseline test for future comparison in only 11 (9.82%) other 
patients whose follow up bone scans were static as compared to 
baseline scan and hence no further radiological imaging tests were 
done in these patients. 
 Finally, the true positivity of baseline bone scan in early breast 
cancer patients (stage I & II), in our study was, 3.57%. Coleman et al 
[46] also reported 4% true positivity across all the stage of breast 
cancer. Another study by Yeh KA et al [47] reported 11% positive 
predictive value of baseline bone scans in T1-2 breast cancer patients. 
 The overall survival & DFS, of our study group, at 5yr and 10 
years was 87%,80% and 75%,68% respectively.  
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CONCLUSION 
 As a policy, the institute has been performing bone scan for 
early stage breast cancer patients for the past 15 years. This 
retrospective analysis shows a low positive predictive value of 
baseline radionuclide bone scans in this group of patients, especially 
in those with primary tumour less than 3cms. Also, the usefulness of 
these scans as baseline test for future comparison proved to be limited 
to about 10% of the patients. 
 Thus, we recommend that baseline radionuclide bone scans can 
be avoided in early stage breast cancer patients except in those who 
are symptomatic & in patients with primary tumour more that 3cm in 
size with or without clinically significant axillary lymph nodes. 
 
 
 
 
56 
 
 
BIBLIOGRAPHY 
1. Coleman RE, Rubens RD. The clinical course of bone metastases 
from breast cancer. Br J Cancer 1987; 55: 61–66. 
2. An Evaluation of Bone Scans as Screening Procedures for Occult 
Metastases in Primary Breast Cancer. R robinson baker, Edwin R. 
Holmes, Philip 0. Alderson, Nagi F. Khouri, Henry N. Wagner, JR. 
Annual Meeting of the American Surgical Association. Boca 
Raton, Florida, March 23-25, 1977. 
3. MckillopJH. Bone scanningin metastatic disease. Fogelman I, ed. 
Bone scanning in clinical practice.New York: Springer-Verlag, 
1987:41-60. 
4. SpencerGR, Khan M, Bird C, Seymour R, Brown TR, Coffins CD. 
Is bone scanning ofvalue in patients with breast cancer? 
ActaChirScand 1981; 147:247-248. 
5. Bishop HM, BlarneyRW, Morris MI, et al. Bone scanning its lack 
of value in the follow-up of patients with breast cancer. BrJSurg 
1979; 66:752-754. 
57 
 
6.  Baker RB., Holmes ER, Alderson P0, Khouri NF, Wagner HN. An 
evaluation of bone scans as screening procedures for occult 
metastases in primary breast cancer. AnnSurg 1977; 186:363-367 
7. Perez DJ, Powles TJ, Milan J et al. Detection of breast carcinoma 
metastases in bone: relative merits of xrays and skeletal 
scintigraphy. Lancet 1983; (ii):613-616. 
8. Swaminathan R, Shanta V, Balasubramanian S, Sampath P. Madras 
Metropolitan Tumour Registry Technical Report 2009-2010. 
National Cancer Registry Program, Cancer Institute (WIA), 
Chennai, 2013. 
9. GLOBOCAN 2102, International Agency for Research on Cancer: 
Estimated Cancer Incidence, Mortality & Prevalence Worldwide in 
2012 
10. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer 
incidence and mortality in Europe in 2006. Ann Oncol 
2007;18(3):581. 
11. Shanta V, Swaminathan R and Rama R. Hospital Cancer Registry, 
Biennial Report: 2009-10.National Cancer Registry Program, 
Cancer Institute (WIA), Chennai. 
58 
 
12. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. 
The global picture. Eur J Cancer 2001;37(Suppl 8):4. 
13. Ries L, Eisner M, Kosary CL, et al. SEER cancer statistics review, 
1975-2001. Bethesda, MD: National Cancer Institute, 2004. 
14. Koscielny S, Tubiana M, Le MG, et al: Breast cancer: Relationship 
between the size of the primary tumour and the probability of 
metastatic dissemination. Br J Cancer 49:709-715, 1984 
15. Tubiana M, Koscielny S: Natural history of human breast cancer: 
Recent data and clinical implications. Breast Cancer Res Treat 
18:125-140, 1991  
16. Tubiana M, Koscielny S: The natural history of breast cancer: 
Implications for a screening strategy. Int J RadiatOncolBiolPhys 
19:1117-1120, 1990 
17. Rosen PP, Groshen S, Saigo PE, et al: A long-term follow-up 
study of survival in stage I (T1M0) and stage II (T1N1) breast 
carcinoma. J ClinOncol 7:355-366, 1989 
18. Golshan M. Chapter 36: Mastectomy, in Harris JR, Lippman ME, 
Morrow M, Osborne CK. Diseases of the Breast, 4th edition. 
Lippincott Williams and Wilkins, 2010. 
59 
 
19. Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman 
GD, Smith MR: The science and practice of bone health in 
oncology: managing bone loss and metastasis in patients with solid 
tumors. J NatlComprCancNetw 2009, 7 Suppl 7:S1-29; quiz S30 
20. Mundy GR: Bone Remodeling and its Disorders. London: Martin 
Dunitz Ltd; 1999. 
21. Scheid V, Buzdar AU, Smith TL, et al. Clinical course of breast 
cancer patients with osseous metastasis treated with combination 
chemotherapy. Cancer 1986;58:2589–2593. 
22. ZamboninZallone A, Teti A, Primavera MV: Resorption of vital or 
devitalized bone by isolated osteoclasts in vitro. The role of lining 
cells.Cell Tissue Res 1984, 235:561-564. 
23. Hadjidakis DJ, Androulakis II: Bone remodeling.Ann N Y 
AcadSci 2006, 1092:385-396. 
24. Guise TA: Parathyroid hormone-related protein and bone 
metastases.Cancer 1997, 80(8 Suppl):1572-1580. 
25. Karaplis AC, Goltzman D: PTH and PTHrP effects on the 
skeleton.RevEndocrMetabDisord 2000, 1:331-341 
60 
 
26. JemalA,SiegelR,WardE,Murray T,XU J,Thun MJ: Cancer 
Statistics 2007.CA cancer J clin 2007,57:43-66 
27. Coleman RE: Clinical features of metastatic bone disease and risk 
of skeletal morbidity. Clin cancer Res 2006,12:6243s-6249s. 
28. Coleman RE. Metastatic bone disease: clinical features, 
pathophysiology and treatment strategies. Cancer Treat Rev 
2001;27:165–176. 
29. Hoegler D. Radiotherapy for palliation of symptoms in incurable 
cancer. CurrProbl Cancer. 1997;21:129–183. 
30. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, 
Rogers MJ. Nitrogen-containing bisphosphonates inhibit the 
mevalonate pathway and prevent post-translational prenylation of 
GTP-binding proteins, including Ras. J Bone Miner 
Res. 1998;13(4):581–589.  
31. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity 
relationships for inhibition of farnesyl diphosphate synthase in 
vitro and inhibition of bone resorption in vivo by nitrogen-
containing bisphosphonates.J Pharmacol Exp Ther. 2001; 
296(2):235–242. 
61 
 
32. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term 
prevention of skeletal complications of metastatic breast cancer 
with pamidronate. J ClinOncol 1998; 16: 2038–2044.  
33. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate 
reduces skeletal morbidity in women with advanced breast cancer 
and lytic bone lesions: a randomized, placebo-controlled trial. 
Protocol 18 Aredia Breast Cancer Study Group. J ClinOncol 
1999; 17: 846–854.   
34. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate 
prevents skeletal complications and is effective palliative 
treatment in women with breast carcinoma and osteolytic bone 
metastases: long term fol- low-up of two randomized, placebo-
controlled trials. Cancer 2000; 88: 1082–109 
35. Rosen LS, Gordon D, Kaminski M et al. Long-term efﬁcacy and 
safety of zoledronic acid compared with pamidronate disodium in 
the treatment of skeletal complications in patients with advanced 
multiple myeloma or breast carcinoma. A randomized, double-
blind, multicenter, comparative trial. Cancer 2003; 98: 1735–
1744. 
62 
 
36. Major PP, Cook RJ, Chen B-L, Zheng M. Multiple event analysis 
of zoledronic acid trials in patients with cancer metastatic to 
bone. Proc Am SocClinOncol 2003; 22: 762 (Abstr 3062).  
37. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is 
superior to pamidronate for the treatment of bone metastases in 
breast carcinoma patients with at least one osteolytic lesion. 
Cancer 2004; 100: 36–43 
38. Coleman R, Gralow J, Bell R, Lipton A. Zoledronic acid is being 
investigated for the prevention of bone metastases in patients 
with early stage cancer. Seventh Workshop on 
Bisphosphonates—From the Laboratory to the Patient. What is 
New in Bisphosphonates? 24–26 March 2004, Davos, 
Switzerland, Poster 66. 
39. Lipton A: Emerging role of bisphosphonates in the clinic--
antitumor activity and prevention of metastasis to bone.Cancer 
Treat Rev 2008, 34(Suppl 1):S25-30. 
40. Stopeck A: Denosumab findings in metastatic breast 
cancer.ClinAdvHematolOncol 2010, 8:159-160. 
63 
 
41. Grey A: Teriparatide for bone loss in the jaw.NEngl J Med 2010, 
363:2458-2459. 
42. Strender LE, LagergrenC,Wallgren A et al: Role of bone scan in 
the initial assessment of operable patients with breast 
caner.Actaradiol. Radiat. Phys. Biol;20:187-191,1981. 
43. Naoki Niikura, Colleen M. Costelloe, John E. Madewell, Naoki 
Hayashi et al: FDG-PET/CT Compared with Conventional 
Imaging in the Detection of Distant Metastases of Primary Breast 
Cancer; published online in THE ONCOLOGIST Express on July 
17, 2011. 
44. Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the 
evaluation of bony metastases in patients with breast cancer: 
comparison with 99Tcm-MDP bone scintigraphy. Nucl Med 
Commun. 2001;22:875-879. 
45. Mitsuru Koizumi, Masataka Yoshimoto, Fujio Kasumi &Etsuro 
Ogata: What do breast cancer patients benefit from staging bone 
scintigraphy? Jpn J ClinOncol 2001;31(6)263-269 
64 
 
46. R E Coleman, R D Rubens, &I.Fogelman: Reappraisal of the 
baseline bone scan in breast cancer. J Nucl Med 29:1045-1049, 
1988. 
47. Yeh KA, Fortunato L, Ridge JA, Hoffman JP, Eisenberg BL. 
Routine bone scanning in patients with T1 and T2 breast cancer: a 
waste of money. Ann SurgOncol. 1995 Jul;2(4):319-324. 
48. Samant R, Ganguly P. Staging investigations in patients with 
breast cancer: the role of bone scans and liver imaging.Arch 
Surg. 1999 May;134(5):551-3; discussion 554. 
49. Lagrange JL, Hoch M, Courdi A, Darcourt J, Benoiel J, Namer 
M, et al. Breast cancer: the role of scintigraphy in the initial 
evaluation & follow up of patients with small tumours (T less 
than or equal to 3 cm). Bull Cancer 1988;75:271-280.  
50. Lee YN. Bone scanning in patients with early stage breast cancer. 
Should it be a routine staging procedure? Cancer. 1982;47:486-
495 
51. Wickerham L, Fisher B, Cronin W. The efficacy of bone 
scanning in the follow up of patients with operable breast cancer. 
Breast cancer Res Treat.1984;4:303-307 
65 
 
52. Baker RR. Preoperative assessment of the patients with breast 
cancer. Surg Clin of North Am.1984;64:1039-1050 
53. El-Domeiri AA, Shroff S. Role of preoperative bone scanning in 
carcinoma of breast. Surg Gynaecol Obstet.1976;142:722-724. 
 
